NAS:BVXV (Israel) Also trade in: Germany Israel

BiondVax Pharmaceuticals Ltd

$ 5.92 0.03 (0.51%)
Volume: 1,738 Avg Vol (1m): 6,577
Market Cap $: 38.69 Mil Enterprise Value $: 47.42 Mil
P/E (TTM): 0.00 P/B: 0.00
Earnings Power Value -8.05
Net Current Asset Value -4.33
Tangible Book -1.92
Projected FCF -14.66
Median P/S Value 0
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 4/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 0.65
Cash-To-Debt ranked higher than
83.95% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
BVXV: 0.65
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.65, Med: 10000, Max: 10000
Current: 0.65
0.65
10000
Debt-to-Equity -2.90
Debt-to-Equity ranked lower than
100.00% of 500 companies
in the Biotechnology industry.
Industry Max: 35.66, Med: 0.28, Min: 0.01
BVXV: -2.9
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: -3.02, Med: -0.83, Max: 2.95
Current: -2.9
-3.02
2.95
Debt-to-EBITDA -1.53
Debt-to-EBITDA ranked lower than
100.00% of 196 companies
in the Biotechnology industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
BVXV: -1.53
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -1.53, Med: -1.28, Max: -1.28
Current: -1.53
-1.53
-1.28
Piotroski F-Score 2
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -3.81
DISTRESS
GREY
SAFE

Profitability & Growth : 3/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
ROE % -3160.04
ROE ranked lower than
69.26% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
BVXV: -3160.04
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -3160.04, Med: -40.69, Max: -31.05
Current: -3160.04
-3160.04
-31.05
ROA % -87.09
ROA ranked lower than
68.17% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
BVXV: -87.09
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -93.56, Med: -35.06, Max: -25.72
Current: -87.09
-93.56
-25.72
ROC (Joel Greenblatt) % -254.47
ROC (Joel Greenblatt) ranked higher than
55.41% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
BVXV: -254.47
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -522.27, Med: -404.52, Max: -188.1
Current: -254.47
-522.27
-188.1
3-Year Total EBITDA Growth Rate -90.60
3-Year EBITDA Growth Rate ranked lower than
85.41% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
BVXV: -55.4
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: 0, Med: 0, Max: -55.4
Current: -55.4
0
-55.4
3-Year EPS w/o NRI Growth Rate -100.00
3-Year EPS w/o NRI Growth Rate ranked lower than
96.59% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
BVXV: -100
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: 0, Max: -100
Current: -100
0
-100

» BVXV's 30-Y Financials

Financials (Next Earnings Date: 2019-08-22)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:BVXV

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 0    SIC : 0
Compare XCNQ:SUN XPAR:ALERS OSTO:ENZY TSX:ONC AMEX:ATNM ASX:BIT XBRU:BOTHE ROCO:4169 NAS:OMED XSWX:KURN ROCO:6564 ROCO:6634 OSTO:LIDDS NAS:HTBX NAS:ONCS ASX:PYC NAS:PDSB XCNQ:BE ROCO:6662 TSXV:NVH
Traded in other countries 2F5.Germany
Address 14 Einstein Street, PO Box 4143, Ness Ziona, Ness Ziona, ISR, 74036
BiondVax Pharmaceuticals Ltd is engaged in the healthcare sector. Its main activity is the commercialization and manufacturing of flu vaccine. Its product is designed to provide multi-season and multi-strain protection against some human influenza virus strains, including both seasonal and pandemic flu strains. The company recently concluded two Phase I/II trials in which the multimeric-001 universal flu vaccine was shown to be safe and immunogenic.

Ratios

Current vs industry vs history
EV-to-EBIT -2.75
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
BVXV: -2.75
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -14.08, Med: 0, Max: 0
Current: -2.75
-14.08
0
EV-to-EBITDA -2.78
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
BVXV: -2.78
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -14.99, Med: 0, Max: 0
Current: -2.78
-14.99
0
Current Ratio 3.45
Current Ratio ranked higher than
62.66% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
BVXV: 3.45
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 3.45, Med: 19.59, Max: 31.16
Current: 3.45
3.45
31.16
Quick Ratio 3.45
Quick Ratio ranked higher than
63.41% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
BVXV: 3.45
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 3.45, Med: 19.59, Max: 31.16
Current: 3.45
3.45
31.16

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -13.00
3-Year Share Buyback Rate ranked lower than
51.93% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
BVXV: -13
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -14.2, Med: 0, Max: 0
Current: -13
-14.2
0

Valuation & Return

Current vs industry vs history
Earnings Yield (Joel Greenblatt) % -36.47
Earnings Yield (Greenblatt) ranked lower than
80.30% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
BVXV: -36.47
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -488.38, Med: 0, Max: 0
Current: -36.47
-488.38
0

More Statistics

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 2
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy N
Less Shares Outstanding yoy Y
Higher Gross Margin yoy N
Higher Asset Turnover yoy N